These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 521060)

  • 61. Inhibition of macrophage-mediated tumor cell destruction by oxidized lipoproteins.
    Justement LB; Patel ST; Newman HA; Zwilling BS
    J Natl Cancer Inst; 1984 Aug; 73(2):469-74. PubMed ID: 6589438
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dependence on antigen dose and timing in the immune response of C3H mice to malignant ascites cells.
    Laursen ML; Laursen K
    Immunology; 1980 Jul; 40(3):403-10. PubMed ID: 7429535
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Xenogeneic serum-induced murine cytotoxic cells. I. The generation of effector components specific for self and allogeneic target cells.
    Levy RB; Shearer GM; Kim KJ; Asofsky RM
    Cell Immunol; 1979 Dec; 48(2):276-87. PubMed ID: 116772
    [No Abstract]   [Full Text] [Related]  

  • 64. Surface analysis of early and late MOPC-3 15-EL tumor cells.
    Harris D; Bailey J; Lewis JC; Grover WH; Panetti M; Evans DL; Ruebush MJ; Paulus LK; Burgess D; Hale AH
    Cell Immunol; 1981 Oct; 64(1):119-30. PubMed ID: 7296672
    [No Abstract]   [Full Text] [Related]  

  • 65. Induction of cell-mediated cytotoxicity by lipoprotein containing histocompatibility antigens.
    Dennert G
    Immunology; 1979 Dec; 38(4):757-63. PubMed ID: 521060
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro.
    Ando K; Nakashima I; Nagase F; Isobe K; Kawashima K; Hasegawa Y; Yoshida T; Iwamoto T; Hasegawa T; Muro Y
    J Immunol; 1988 Feb; 140(3):723-9. PubMed ID: 2448374
    [TBL] [Abstract][Full Text] [Related]  

  • 67. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
    Gorelik E; Gunji Y; Herberman RB
    J Immunol; 1988 Mar; 140(6):2096-102. PubMed ID: 3126240
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
    Hinuma S; Naruo K; Shiho O; Tsukamoto K
    Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
    Sensi ML; Parenza M; Parmiani G
    J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT; Eisenthal A; Rosenberg SA
    J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhibition of lymphocyte-mediated cytotoxicity (51Cr-release) by antisera preabsorbed with various cells.
    Sendo F; Aoki T; Buafo CK
    J Natl Cancer Inst; 1974 Mar; 52(3):769-75. PubMed ID: 4857026
    [No Abstract]   [Full Text] [Related]  

  • 72. Blocking of syngeneic effector T cells by soluble tumour antigens.
    Plata F; Levy JP
    Nature; 1974 May; 249(454):271-4. PubMed ID: 4545403
    [No Abstract]   [Full Text] [Related]  

  • 73. Studies on the induction and expression of T cell-mediated immunity. I. Blocking of cell-mediated cytolysis by membrane antigens.
    Bonavida B
    J Immunol; 1974 Mar; 112(3):926-34. PubMed ID: 4544178
    [No Abstract]   [Full Text] [Related]  

  • 74. Cell-mediated cell lysis in vitro: genetic control of killer cell production and target specificities in the mouse.
    Nabholz M; Vives J; Young HM; Meo T; Miggiano V; Rijnbeek A; Shreffler DC
    Eur J Immunol; 1974 May; 4(5):378-87. PubMed ID: 4277395
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.